ArticleScientific reports2025
One-year outcomes of trabeculectomy with mitomycin C in secondary glaucoma due to posner-schlossman syndrome.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To explore the effectiveness and safety of surgical treatment for patients with Posner-Schlossman syndrome (PSS) accompanied by optic nerve Changes. A retrospective analysis was conducted on 15 cases (15 eyes) of glaucoma secondary to PSS who underwent trabeculectomy from January 2018 to March 2023 at Chongqing Aier Eye Hospital. Preoperative and postoperative conditions, as well as intraocular pressure (IOP) during postoperative recurrences, were compared. 15 eyes underwent trabeculectomy, with diffuse and mildly elevated filtering blebs postoperatively, without Choroidal detachment or macular edema. The preoperative IOP was 30.91 ± 11.75 mmHg (mean ± SD), and patients used 2.60 ± 0.91 types of antiglaucoma medication. At 12 months postsurgery, the mean IOP was 12.09 ± 2.33 mmHg, and no antiglaucoma medications were used thereafter (both P < 0.05). Nine eyes experienced recurrence of PSS, with IOP during recurrences being lower than preoperative levels. Except for one eye with an IOP of 24 mmHg, the other eight eyes had IOPs not exceeding 21 mmHg. Trabeculectomy is a safe and effective treatment for patients with PSS during episodes with optic nerve damage, and it can reduce the peak IOP during recurrences, preventing further optic nerve damage from high IOP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.